Q-omics provides the consensus-scored KIAA1143 profile across patient tissues and cancer cell-line models. KIAA1143 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIAA1143 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, KIAA1143 protein abundance shows 23,420 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where KIAA1143 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1143 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1143 survival associations across molecular data types. KIAA1143 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1143 RNA expression–survival associations across cancer types. High KIAA1143 expression shows unfavorable associations in LIHC, KICH and LUSC, but favorable associations in KIRC, COAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIAA1143 RNA expression.
This table summarizes KIAA1143 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1143. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1143 shows lower tumor expression in THCA, KIRC, UCEC, KICH and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher KIAA1143 RNA expression in normal versus tumor tissue (log2 FC = −0.454, t-test p < 0.001).
This table shows molecular features associated with KIAA1143 in patient tissues and cancer cell lines. In patient samples, KIAA1143 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1143 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
